Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Neurocrine Biosciences Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $25.35 (market cap $141.17B), while Neurocrine Biosciences Inc trades at $170.05 (market cap $17.51B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 8.1× Neurocrine Biosciences Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.25% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| BBVA | NBIX | |
|---|---|---|
Market Cap | $141.17B | $17.51B |
Sector | Financials | Health |
52-Week High | $26.14 | $180.55 |
52-Week Low | $14.73 | $123.10 |
Dividend Yield | 4.25% | — |
Enterprise Value | — | $16.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $25.39, down 1.17% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 26.51% net income margin and 18.67% ROE. Recent earnings beat expectations in Q1 2026, and revenue has grown steadily from $28.2B in 2022 to $39.4B in 2025. Positive analyst sentiment is reflected in a 53.85% buy rating, though legal and regulatory risks from ongoing probes in Spain present headwinds.
The outlook for BBVA remains positive given robust profitability and analyst support, but investors should weigh the stock's attractive valuation against litigation risks and sector volatility. Upside potential exists if earnings continue to exceed forecasts, but legal developments could pressure the share price near-term.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
